Genetic counseling for breast cancer risk: General concepts, challenging themes and future directions

Breast Disease

Volumn 27, Issue 1, 2007, Pages 69-96

  Moglia, Diana M ^b   Brown, Karen L ^a   Grumet, Sherry ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Good Samaritan Hospital Medical Center   (United States)

^c MONMOUTH MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Cancer risk; Decision aids; Genetic counseling; Genetic testing; Hereditary breast cancer syndromes; Informed consent; Psychosocial assessment; Test result interpretation

Indexed keywords

ANAMNESIS; BREAST CANCER; CANCER RISK; CARCINOGENESIS; GENE MUTATION; GENETIC COUNSELING; GENETIC HETEROGENEITY; GENETIC PROCEDURES; GENETIC SUSCEPTIBILITY; HUMAN; INFORMED CONSENT; MUTAGEN TESTING; PATIENT COUNSELING; PEDIGREE ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSOCIAL CARE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 35248883051     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2007-27105     Document Type: Review

References (129)

1. B.P. Alter, P.S. Rosenberg and L.C. Brody, Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2, J Med Genet 44 (2007), 1-9.
2. American College of Medical Genetics Board of Directors, ACMG statement on direct-to-consumer genetic testing, Genet Med 6 (2004), 60.
3. American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility, J Clin Oncol 21 (2003), 2397-2406.
4. L.B. Andrews, J.E. Fullarton, N.A. Holtzman and A.G. Motulsky, Assessing Genetic Risks: Implications for Health and Social Policy, National Academy Press, Washington, D.C., 1994.
5. A. Antoniou, P.D. Pharoah, S. Narod, H.A. Risch, J.E. Eyfjord, J.L. Hopper, N. Loman, H. Olsson, O. Johannsson, A. Borg, B. Pasini, P. Radice, S. Manoukian, D.M. Eccles, N. Tang, E. Olah, H. Anton-Culver, E. Warner, J. Lubinski, J. Gronwald, B. Gorski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjakoski, O.P. Kallioniemi, D. Thompson, C. Evans, J. Peto, F. Lalloo, D.G. Evans and D.F. Easton, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies, Am J Hum Genet 72 (2003), 1117-1130.
6. J. Audrain, M.D. Schwartz, C. Lerman, C. Hughes, B.N. Peshkin and B. Biesecker, Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: The contributions of personality and appraisal, Ann Behav Med 19 (1997), 370-377.
7. A.D. Auerbach, O. Levran, B. Mullaney, D. Kutler, K. Mah, S.D. Batish, R. Diotti, K. Pujara, A. Deffenbaugh, T. Scholl, K. Nafa, N. Ellis, M. Berwick, M. MacMillan, H. Schneider, K. Offit, J. Wagner and H. Hanenberg, IFAR 2003: Unique phenotype associated with biallelic BRCA2 mutations includes high risk of brain tumors, Wilms tumors and early onset acute leukemia, Fifteenth Annual Fanconi Anemia Research.
8. R.B. Bar-Sade, A. Kruglikova, B. Modan, E. Gak, G. Hirsh-Yechezkel, L. Theodor, I. Novikov, R. Gershoni-Baruch, S. Risel, M.Z. Papa, G. Ben-Baruch and E. Friedman, The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim, Hum Mol Genet 7 (1998), 801-805.
9. L.M. Baudhuim, L.J. Burgart, O. Leontovich and S.N. Thibodeau, Use of microsatellite instability and immunohistochemisty testing for the identification of individuals at risk for Lynch syndrome, Fam Cancer 4 (2005), 255-265.
10. R.L. Bennett, K.A. Steinhaus, S.B. Uhrich, C.K. O'Sullivan, R.G. Resta, D. Lochner-Doyle et al., Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet 56 (1995), 745-752.
11. D.B. Berman, J. Wagner-Costalas, D.C. Schultz, H.T. Lynch, M. Daly and A.K. Godwin, Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: A genetic study of 15 185delAG-mutation kindreds, Am J Hum Genet 58 (1996), 1166-1176.
12. D.A. Berry, E.S. Iversen Jr., D.F. Gudbjartsson, E.H. Hiller, J.E. Garber, B.N. Peshkin, C. Lerman, P. Watson, H.T. Lynch, S.G. Hilsenbeck, W.S. Rubinstein, K.S. Hughes and G. Parmigiani, BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes, J Clin Oncol 20 (2002), 3936-3937.
13. T.L. Bodd, J. Reichelt, K. Heimdal and P. Moller, Uptake of BRCA1 testing in adult sisters and daughters of known mutation carriers in Norway, J Genet Couns 12 (2003), 405-417.
14. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium, J Natl Cancer Inst 91 (1999), 1310-1316.
15. CTM Brekelmans, C. Seynaeve, CCM Bartels, MMA Tilanus-Linthorst, E.J. Meiers-Heijboer, CMG Crepin, AN van Geel, M. Menke, L.C. Verhoog, A. vd Ouweland, AIM Obdeijn and JGM Klijn, Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk, J Clin Oncol 19 (2001), 924-930.
16. P. Broet, A. de la Rochefordiere, S.M. Scholl, A. Fourquet, V. Mosseri, J.C. Durand, P. Pouillart and B. Asselain, Contralateral breast cancer: annual incidence and risk parameters, J Clin Oncol 13 (1995), 1578-1583.
17. CHEK2 Breast Cancer Case-Control Consortium. CHEK2* 1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies, Am J Hum Genet 74 (2004), 1175-1182.
18. A. Chompret, L. Brugieres, M. Ronsin, M. Gardes, F. Dessarps-Freichey, A. Abel, D. Hua, L. Ligot, M.G. Dondon, B. Bressac-de Paillerets, T. Frebourg, J. Lemerle, C. Bonaiti-Pellie and J. Feunteun, P53 germline mutations in childhood cancers and cancer risk for carrier individuals, Brit J Cancer 82 (2000), 1932-1937.
19. P.A. Daly, C. Nolan, A. Green, W. Ormiston, N. Cody, T. McDevitt, B. O'hIci, D. Byrne, E. McDermott, D.N. Carney, N. O'Higgins and D.E. Barton, Predictive testing for BRCA1 and 2 mutations: A male contribution, Ann Oncol 14 (2003), 549-553.
20. A.M. Deffenbaugh, T.S. Frank, M. Hoffman, L. Cannon-Albright and S.L Neuhausen, Characterization of common BRCA1 and BRCA2 variants, Genet Test 6 (2002), 119-121.
21. T.A. DeMarco, B.N. Peshkin and B.M. Brogan, Across the spectrum: Case studies in genetic counseling for breast and ovarian Cancer, J Genet Couns 10 (2001), 379-395.
22. F.S. Douglas, L.C. O'Dair, M. Robinson, D.G. Evens and S.A. Lynch, The accuracy of diagnosis as reported in families with cancer: A retrospective study, J Med Genet 36 (1999), 309-312.
23. M.R. Dufault, B. Betz, B. Wappenschmidt, W. Hofmann, K. Bandick, A. Golla, A. Pietschmann, C. Nestle-Kramling, K. Rhiem, C. Huttner, C. von Lindern, P Dall, M. Kiechle, M. Untch, W. Jonat, A. Meindl, S. Scherneck, D. Niederacher, R.K. Schmutzler and N. Arnold, Limited relevance of the CHEK2 gene in hereditary breast cancer, Int J Cancer 110 (2004), 320-325.
24. D.F. Easton, D. Ford and D.T. Bishop, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium., Am J Hum Genet 56 (1995), 265-271.
25. M.L. Eaton, Surrogate decision making for genetic testing for Alzheimer disease, Genet Test 3 (1999), 93-97.
26. D.G. Evans, F. Lalloo, P. Hopwood, A. Maurice, A. Baildam, A. Brain, L. Barr and A. Howell, Surgical decisions made by 158 women with hereditary breast cancer aged <50 years, Eur J Surg Oncol 31 (2005), 1112-1118.
27. D.G. Evans, J.M. Birch, R.T. Ramsden, S. Sharif and M.E. Baser, Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks for certain tumour prone syndromes, J Med Genet 43 (2006), 289-294.
28. J.L. Fitzpatrick, C. Hahn, T. Costa and M.J. Huggins, The Duty to Recontact: Attitudes of Genetic Service Providers, Am J Hum Genet 64 (1999), 852-860.
29. D. Ford, D.F. Easton, D.T. Bishop et al., Risks of cancer in BRCA1 mutations carriers, Lancet 343 (1994), 692-695.
30. T.S. Frank, A.M. Deffenbaugh, J.E. Reid, M. Hulick, B.E. Ward, B. Lingenfelter, K.L. Gumpper, T. Scholl, S.V. Tavtigian, D.R. Pruss and G.C. Critchfield, Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals, J Clin Oncol 20 (2002), 1480-1490.
31. E. Friedman, R. Bar-Sade Bruchim, A. Kruglikova, S. Risel, E. Levy-Lahad, D. Halle, E. Bar-On, R. Gershoni-Baruch, E. Dagan, I. Kepten, T. Peretz, I. Lerer, N. Wienberg, A. Shushan and D. Abeliovich, Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes, Am J Hum Genet 63 (1998), 1224-1227.
32. G. Goelen, A. Rigo, M. Bonduelle and J. De Greve, Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing, J Clin Oncol 17 (1999), 1595-1600.
33. M.J. Green, S.K. Peterson, M.W. Baker, G.R. Harper, L.C. Friedman, W.S. Rubinstein and D.T. Mauger, Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility, JAMA 292 (2004), 442-452.
34. M.J. Green, S.K. Peterson, M.W. Baker, L.C. Friedman, G.R. Harper, W.S. Rubinstein, J.A. Peters and D.T. Mauger, Use of an educational computer program before genetic counseling for breast cancer susceptibility: Effects on duration and content of counseling sessions, Genet Med 7 (2005), 221-229.
35. A. Gustafsson, P.I. Tartter, S.T. Browser and G. Lesnick, Prognosis of patients with bilateral carcinoma of the breast, J Am Coll Surg 178 (1994), 111-116.
36. B.G. Haffty, E. Harrold, A.J. Khan, P. Pathare, T.E. Smith, B.C. Turner, P.M. Glazer, B. Ward, D. Carter, E. Matloff, A.E. Bale and M. Alvarez-Franco, Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status, Lancet 359 (2002), 1471-1477.
37. C.H. Halbert, L. Wenzel, C. Lerman, B.N. Peshkin, S. Narod, A. Marcus, C. Corio, T. DeMarco and S. Bellamy, Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations, Cancer Epidemiol Biomark Prev 13 (2004), 875-881.
38. N. Hallowell, A. Ardern-Jones, R. Eeles, C. Foster, A. Lucassen, C. Moynihan and M. Watson, Men's decision-making about predictive BRCA1/ 2 testing: The role of family, J Genet Couns 14 (2005), 207-216.
39. A.W. Helmes, J.O. Culver and D.J. Bowen, Results of a randomized study of telephone versus in-person breast cancer risk counseling, Patient Educ Couns 64 (2006), 96-103.
40. B.C. Hendrickson, T. Judkins, B.D. Ward, K. Eliason, A.E. Deffenbaugh, L.A. Burbidge, K. Pyne, B. Leclair, B.E. Ward and T. Scholl, Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ ovarian cancer families, Genes Chromosomes Cancer 43 (2005 , 309-313.
41. L.J. Herrinton, W.E. Barlow, O. Yu, A.M. Geiger, J.G. Elmore, M.B. Barton, E.L. Harris, S. Rolnick, R. Pardee, G. Husson, A. Macedo and S.W. Fletcher, Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project, J Clin Oncol 23 (2005), 4275-4286.
42. K. Hirschhorn, L.D. Fleisher, L. Godmilow, R.R. Howell, R.R. Lebel, E.R.B. McCabe, M.J. McGinniss, A. Milunsky, M.Z. Pelias, R.E. Pyertiz, E. Sujansky, B.H. Thompson and R. Zinberg, Duty to Re-Contact, An American College of Medical Genetics Policy Statement, Genet Med 1 (1999), 171-172.
43. N.A. Holtzman and M.S. Watson, Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing, Johns Hopkins University Press, Baltimore, MD, 1998.
44. N. Hoogerbrugge, P. Bult, L.M. de Widt-Levert, L.V. Beex, L.A. Kiemeney, M.J. Ligtenberg, L.F. Massuger, C. Boetes, P. Manders and H.G. Brunner, High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer, J Clin Oncol 21 (2003), 41-45.
45. N.G. Howlett, NG, T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz, C. Die-Smulders, N. Persky, M. Grompe, H. Joenje, G. Pals, H. Ikeda, E.A. Fox and A.D. D'Andrea, Biallelic inactivation of BRCA2 in Fanconi anemia, Science 297 (2002), 606-609.
46. Human Genetics Commission, Genes direct: Ensuring the effective oversight of genetic tests supplied directly to the public, London, UK: Department of Health, 2003.
47. A.G.W. Hunter, N. Sharpe, M. Mullen and W.S. Meschino, Ethical, legal, and practical concerns about recontacting patients to inform them of new information: The case in medical genetics, Am J Med Genet 103 (2001), 265-276.
48. C. Julian-Reynier, H. Sobol, C. Sevilla, C. Nogues, P. Bourret and French Cancer Genetic Network. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network.Psychooncology 9 (2000), 504-510.
49. K.M. Kash, J.C. Holland, M.P. Osborne and D.G. Miller, Psychological counseling strategies for women at risk of breast cancer, J Natl Cancer Inst Monogr 17 (1995), 73-79.
50. N.D. Kauff, P. Perez-Segura, M.E. Robson, L. Scheuer, B. Siegel, A. Schluger, B. Rapaport, T.S. Frank, K. Nafa, N.A. Ellis, G. Parmigiani and K. Offit, Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39 (2002), 611-614.
51. N.D. Kauff, E. Brogi, L. Scheuer, D.R. Pathak, P.I. Borgen, C.A. Hudis, K. Offit and M.E. Robson, Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations, Cancer 97 (2003), 1601-1608.
52. N.D. Kauff, N. Mitra, M.E. Robson, K.E. Hurley, S. Chuai, D. Goldfrank, E. Wadsworth, J. Lee, T. Cigler, P.I. Borgen, L. Norton, R.R. Barakat and K. Offit, Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families, J Natl Cancer Inst 97 (2005), 1382-1384.
53. E.M. Kaufman, B.N. Peshkin, W. Lawrence, R. Shelby, C. Isaacs, K. Brown, J. Rispoli, S. O'Neill, K. Hurley, T. De-Marco, B. Brogan, S. Grumet, L. Jandorf, K. McKenna, H. Valdimarsdottir and M.D. Schwartz, Development of an interactive decision aid for female BRCA1/BRCA2 carriers, J Genet Couns 12 (2003), 109-129.
54. M-C King, J.H. Marks and J.B. Mandell for the New York Breast Cancer Study Group, Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2, Science 302 (2003), 643-646.
55. I.K. Komenaka, B.A. Ditkoff, K.A. Joseph, D. Russo, P. Gorroochurn, M. Ward, E. Horowitz, M.B. El-Tamer and F.R. Schnabel, The development of interval breast malignancies in patients with BRCA mutations, Cancer 100 (2004), 2079-2083.
56. C.K. Kuhl, S. Schrading, C.C. Leutner, N. Morakkabati-Spitz, E. Wardelmann, R. Fimmers, W. Kuhn and H.H. Schild, Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer, J Clin Oncol 23 (2005), 8469-8476.
57. F. Lalloo, J. Varley, D. Ellis, A. Moran, L. O'Dair, P. Pharoah, D. Gareth R. Evans and the Early Onset Breast Cancer Study Group, Prediction of pathogenic mutations in patient with early-onset breast cancer by family history, Lancet 361 (2003), 1101-1102.
58. F. Lalloo, J.Varley, A. Moran, D. Ellis, L. O'Dair, P. Pharoah, A. Antoniou, R. Hartley, A. Shenton, S. Seal, B. Bulman, A. Howell and D. Gareth R. Evans, BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives, Eur J Cancer 42 (2006), 1143-1150.
59. R. Laxova, Testing for cancer susceptibility genes in children, Advances in Pediatrics 46 (1999), 1-40.
60. B. Leegte, A.H. van der Hout, A.M. Deffenbaugh, M.K. Bakker, I.M. Mulder, A. ten Berge, E.P. Leenders, J. Wesseling, J. de Hullu, N. Hoogerbrugge, M.J.L. Ligtenberg, A. Arden-Jones, E. Bancroft, A. Salmon, J. Barwell, R. Eeles and J.C. Oosterwijk, Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations, J Med Genet 42 (2005) e20.
61. C. Lerman and R. Croyle, Psychological issues in genetic testing for breast cancer susceptibility, Arch Int Med 154 (1994), 609-616.
62. C. Lerman, E. Lustbader, B. Rimer, M. Daly, S. Miller, C. Sands and A. Balshem, Effects of individualized breast cancer risk counseling: A randomized trial, J Natl Cancer Inst 87 (1995), 286-292.
63. A. Liede, K. Metcalfe, D. Hanna, E. Hoodfar, C. Snyder, C. Durham, H.T. Lynch and S.A. Narod, Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling, Am J Hum Genet 67 (2000), 1494-1504.
64. L. Lodder, P.G. Frets, R.W. Trijsburg, A. Tibben, E.J. Meijers-Heijboer, H.J. Duivenvoorden, A.Wagner, C.A. van der Meer, P. Devilee, C.J. Cornelisse and M.F. Niermeijer, Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: An exploration of attitudes and psychological functioning during genetic testing, Eur J Hum Genet 9 (2001), 492-500.
65. L. Ma, E. Fishell, B. Wright, W. Hanna, S. Allan and N.F. Boyd, Case-control study of factors associated with failure to detect breast cancer by mammography, J Natl Cancer Inst 84 (1992), 781-785.
66. M. Martin, C. Frye, L.A. Burbidge, A.M. Deffenbaugh, D. Pruss and B.E. Ward, Concurrent deleterious mutations in both BRCA1 and BRCA2 in a large series of patients, American Society of Human Genetics 56th Annual Meeting 2006, New Orleans, LA.
67. M.F. McAllister, D.G. Evans, W. Ormiston and P. Daly, Men in breast cancer families: A preliminary qualitative study of awareness and experience, J Med Genet 35 (1998), 739-744.
68. L.L. McCabe and E.R.B. McCabe, Direct-to-consumer genetic testing: access and marketing, Genet Med 6 (2004), 58-59.
69. S.K. McDonnell, D.J. Schaid, J.L. Myers, C.S. Grant, J.H. Donohue, J.E. Woods, M.H. Frost, J.L. Johnson, D.L. Sitta, J.M. Slezak, T.B. Crotty, R.B. Jenkins, T.A. Sellers and L.C. Hartmann, Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer, J Clin Oncol 19 (2001), 3938-3943.
70. V. McGuire, A. Felberg, M. Mills, K.L. Ostrow, R. DiCioccio, E.M. John, D.W.West and A.S. Whittemore, Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations, Am J Epidemiol 160 (2004), 631-618.
71. W. McKinnon, B. Baty, R. Bennett, M. Magee, W. Neufeld-Kaiser, K. Peters, J. Sawyer and K. Schneider, Predisposition genetic testing for late-onset disorders in adults: A position paper of the National Society of Genetic Counselors, JAMA 278 (1997), 1217-1220.
72. H. Meijers-Heijboer, A. van den Ouweland , J. Klijn , M. Wasielewski , A. de Snoo, R. Oldenburg, A. Hollestelle, M. Houben , E. Crepin, M. van Veghel-Plandsoen, F. Elstrodt, C. van Duijn, C. Bartels, C. Meijers, M. Schutte, L. McGuffog, D. Thompson, D. Easton, N. Sodha, S. Seal, R. Barfoot, J. Mangion, J. Chang-Claude, D. Eccles, R. Eeles, D.G. Evans, R. Houlston, V. Murday, S. Narod, T. Peretz, J. Peto, C. Phelan, H.X. Zhang, C. Szabo, P. Devilee, D. Goldgar, P.A. Futreal, K.L. Nathanson, B. Weber, N. Rahman and M.R. Stratton, CHEK2-Breast Cancer Consortium, Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations, Nat Genet 31 (2002), 55-59.
73. S.M. Melzer and S.R. Poole, Reimbursement for telephone care, Pediatrics 109 (2002), 290-293.
74. R.L. Milne, J.A. Knight, E.M. John, G.S. Dite, R. Balbuena, A. Ziogas, I.L. Andrulis, D.W. West, F.P. Li, M.C. Southey, G.G. Giles, M.R.E. McCredie, J.L. Hopper and A.S. Whittemore for the Breast Cancer Family Registry, Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations, Cancer Epidemiol Biomark Prev 14 (2005), 350-356.
75. R. Moslehi, D. Russo, C. Phelan, E. Jack, K. Antman and S. Narod, An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2, Clin Genet 57 (2000), 70-73.
76. A. Musolino, N. Naldi, M. Michiara, M.A. Bella, P. Zanelli, B. Bortesi, M. Capelletti, M. Savi, T.M. Neri and A. Ardizzoni, A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes, Breast Cancer Res Treat 91 (2005), 203-205.
77. Myriad Genetic Laboratories, BART Webcast. Available at http://www.myriadtests.com/downloads/NSGC-BART-Webcast-with-Notes.pdf (accessed December 3, 2006).
78. S.A. Narod, H. Risch, R. Moslehi, A. Dorum, S. Neuhausen, H. Olsson, D. Provencher, P. Radice, G. Evans, S. Bishop, J-S Brunet and B.A.J. Ponder for the Hereditary Ovarian Cancer Clinical Study Group, Oral Contraceptives and the Risk of Hereditary Ovarian Cancer, New Engl J Med 339 (1998), 424-428.
79. S.A. Narod, M-P Dube, J. Klijn, J. Lubinski, H.T. Lynch, P. Ghadirian, D. Provencher, K. Heimdal, P. Moller, M. Robson, K. Offit, C. Issacs, B. Weber, E. Friedman, R. Gershoni-Baruch, G. Rennert, B. Pasini, T. Wagner, M. Daly, J.E. Garber, S.L. Neuhausen, P. Ainsworth, H. Olsson, G. Evans, M. Osborne, F. Couch, W.D. Foulkes, E. Warner, C. Kim-Sing, O. Olopade, N. Tung, H.M. Saal, J. Weitzel, S. Merajver, M. Gauthier-Villars, H. Jernstrom, P. Sun and J.-S. Brunet, Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst 94 (2002), 1773-1779.
80. R). Available at http://www.cancer.gov/cancertopics/pdq/genetics/ risk-assessment-and-counseling (accessed December 4, 2006).
81. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Genetic/Familial High Risk Assessment: Breast and Ovarian V.I. 2006. Available at http://www.nccn.org/professionals/physician_gls/PDF/ genetics_screening.pdf (accessed November 30, 2006).
82. National Institutes of Health, Clinical Trials: Telephone-based genetic counseling or standard genetic counseling in women at risk of carrying the BRCA1 or BRCA2 mutation-Identifier-NCT00287898. Available at http://www.clinicaltrials.gov (accessed 10/13/2006).
83. National Society of Genetic Counselors (2005), Genetic Counseling as a Profession. Available at http://www.nsgc.org/about/definition.cfm (accessed November 21, 2006).
84. S.L. Neuhausen, S. Mazoyer, L. Friedman, M. Stratton, K. Offit, A. Caligo, G. Tomlinson, L. Cannon-Albright, T. Bishop, D. Kelsell, E. Solomon, B. Weber, F. Couch, J. Struewing, P. Tonin, F. Durocher, S. Narod, M.H. Skolnick, G. Lenoir, O. Serova, B. Ponder, D. Stoppa-Lyonnet, D. Easton, M.C. King and D.E. Goldgar, Haplotype and phenotype analysis of six recurrent BRCA1 Mutations in 61 families: Results of an international study, Am J Hum Genet 58 (1996), 271-280.
85. A.M. O'Connor, D. Stacey, V. Entwistle, H. Llewllyn-Thomas, D. Rovner, M. Holmes-Rovner, V. Tait, J. Tetroe, V. Fiset, M. Barry and J. Jones, Decision aids for people facing health treatment or screening decisions. Available at http://www.cochrane.org/reviews/en/ab001431.html (accessed March 14, 2007).
86. K. Offit, H. Pierce, T. Kirchhoff, P. Kolachana, B. Rapaport, P. Gregersen, S. Johnson, O. Yossepowitch, H. Huang, J. Satagopan, M. Robson, L. Scheuer, K. Nafa and N. Ellis, Frequency of CHEK2 ,1100delC in New York breast cancer cases and controls, BMC Med Genet 4 (2003), Epub 2003 Jan 15.
87. K. Offit, K. Kohut, B. Clagett, E.A. Wadsworth, K.J. Lafaro, S. Cummings, M. White, M. Sagi, D. Bernstein and J.G. Davis, Cancer genetic testing and assisted reproduction, J Clin Oncol 24 (2006), 4775-4782.
88. R.A. Oldenburg, K. Kroeze-Jansema, J. Kraan, H. Morreau, J.G. Klijn, N. Hoogerbrugge, M.J. Ligtenberg, C.J. van Asperen, H.F. Vasen, C. Meijers, H. Meijers-Heijboer, T.H. de Bock, C.J. Cornelisse and P. Devilee, The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families, Cancer Res 63 (2003), 8153-8157.
89. K.E. Ormond, J. Haun, L. Cook, D. Duquette, C. Ludowese and A.L. Matthews, Recommendations for telephone counseling, J Genet Couns 9 (2000), 63-71.
90. M.R. Palomares, B. Paz and J.N. Weitzel, Letter to the Editor - Genetic cancer risk assessment in newly diagnosed breast cancer patients is useful and possible in practice, J Clin Oncol 23 (2005), 3165-3166.
91. B.N. Peshkin, T.A. DeMarco, B.M. Brogan, C. Lerman and C. Issacs, BRCA1/2 testing: Complex themes in result interpretation, J Clin Oncol 19 (2001), 2555-2565.
92. S.K. Peterson, R.D. Pentz, A.M. Blanco, P.A. Ward, B.G. Watts, S.K. Marani, L.C. James and L.C. Strong, Evaluation of a decision aid for families considering p53 genetic counseling and testing, Genet Med 8 (2006), 226-233.
93. C.M. Phelan, V. Dapic, B. Tice, R. Favis, E. Kwan, F. Barany, S. Manoukian, P. Radice, R.B. van der Luijt, B.P. Nesselrooij, G. Chenevix-Trench, kConFab, T. Caldes, M. de la Hoya, S. Lindquist, S.V. Tavtigian, D. Goldgar, A. Borg, S.A. Narod and A.N. Monteiro, Classification of BRCA1 missense variants of unknown clinical significance, J Med Genet 42 (2005), 138-146.
94. T.R. Rebbeck, T. Friebel, T. Wagner, H.T. Lynch, J.E. Garber, M.B. Daly, C. Issacs, O.I. Olopade, S.L. Neuhausen, L. van't Veer, R. Eeles, D.G. Evans, G. Tomlinson, E. Matloff, S.A. Narod, A. Eisen, S. Domchek, K. Armstrong and B.L. Weber; PROSE Study Group, Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group, J Clin Oncol 23 (2005), 7804-7810.
95. M. Robson, L. Scheuer, K. Nafa, N. Ellis and K. Offit, Unique de novo mutation of BRCA2 in a woman with early onset breast cancer, J Med Genet 39 (2002), 126-128.
96. M. Robson, T. Svahn, B. McCormick, P. Borgen, C. Hudis, L. Norton and K. Offit, Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2 - a clinic-based series, Cancer 103 (2005), 44-51.
97. P.P. Rosen, S. Groshen, D.W. Kinne and L. Norton, Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/ T2N0M0 patients with long-term follow-up, J Clin Oncol 11 (1993), 2090-2100.
98. I. Rouleau, J. Chiquette, M. Plante, J. Simard and M. Dorval, Changes in health-related behaviours following BRCA1/2 genetic testing: The case of hormone replacement therapy, J Obstet Gynaecol Can 26 (2004), 1059-1066.
99. I. Saarenmaa, T. Salminen, U. Geiger, P. Heikkinen, S. Hyvarinen, J. Isola, V. Kataja, M.L. Kokko, R. Kokko, E. Kumpulanien, A. Karkkainen, J. Pakkanen, P. Peltonen, A. Piironen, A. Salo, M.L. Talviala and M. Haka, The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography, Breast Cancer Res Treat 67 (2001), 117-123.
100. K.K. Sangha, A. Dircks and S. Langlois, Assessment of the effectiveness of genetic counseling by telephone compared to a clinic visit, J Genet Couns 12 (2003), 171-183.
101. M.D. Schwartz, C. Lerman, B. Brogan, B.N. Peshkin, C.H. Halbert, T. DeMarco, W. Lawrence, D. Main, C. Finch, C. Magnant, M. Pennanen, T. Tsangaris, S. Willey and C. Issacs, Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients, J Clin Oncol 22 (2004), 1823-1829.
102. M.D. Schwartz, C. Lerman, B. Brogan, B.N. Peshkin, C. Issacs, T. DeMarco, C.H. Halbert, M. Pennanen and C. Finch, Utilization of BRCA1/ BRCA2 mutation testing in newly diagnosed breast cancer patients, Cancer Epidemiol Biomark Prev 14 (2005), 1003-1007.
103. C. Seynaeve, L.C. Verhoog, L.M.C. van de Bosch, A.N. van Geel, M. Menke-Pluymers, E.J. Meijers-Heijboer, A.M.W. van den Ouweland, A. Wagner, C.L. Creutzberg, M.F. Niermeijer, J.G.M. Klijn and C.T.M. Brekelmans, Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy, Eur J Cancer 40 (2004), 1150-1158.
104. A. Shaag, T. Walsh, P. Renbaum, T. Kirchhoff, K. Nafa, S. Shiovitz, J.B. Mandell, P. Welcsh, M.K. Lee, N. Ellis, K. Offit, E. Levy-Lahad and M.C. King, Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population, Hum Mol Genet 14 (2005), 555-563.
105. K. Shahedi, M. Emanuelsson, F. Wiklund and H. Gronberg, High risk of contralateral breast carcinoma in women with hereditary/familial non- BRCA1/BRCA2 breast carcinoma, Cancer 106 (2006), 1237-1242.
106. N.F. Sharpe, Informed consent and Huntington disease: A model for communication, Am J Med Genet 50 (1994), 239-246.
107. J.E. Soet and C.E. Basch, The telephone as a communication medium for health education, Health Educ Behav 24 (1997), 759-772.
108. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, J Clin Oncol 14 (1996), 1730-1736, discussion 1737-1740.
109. A.J. Stolier and R.L. Corsetti, Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation, Am Surg 71 (2005), 1031-1033.
110. C.I. Szabo and M.C. King, Populations genetics of BRCA1 and BRCA2, Am J Hum Genet 60 (1997), 1013-1020.
111. T. Taniguchi and A.D. D'Andrea, The molecular pathogenesis of Fanconi anemia: Recent progress, Blood 107 (2006), 4223-4233.
112. A. Tesoriero, C. Andersen, M. Southey, G. Somers, M. McKay, J. Armes, M. McCredie, G. Giles, J.L. Hopper and D. Venter, De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation, Am J Hum Genet 65 (1999), 567-569.
113. M. Tilanus-Linthorst, L. Verhoog, I.M. Obdeijn, K. Bartels, M. Menke-Pluymers, A. Eggermont, J. Klijn, H. Meijers-Heijboer, T. van der Kwast and C. Brekelmans, A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography, Int J Cancer 102 (2002), 91-95.
114. M.D. Tischkowitz and S.V. Hodgson, Fanconi anaemia, J Med Genet 40 (2003), 1-10.
115. A. Trepanier, M. Ahrens, W. McKinnon, J. Peters, J. Stopfer, S.C. Grumet, S. Manley, J.O. Culver, R. Acton, J. Larsen-Haidle, L.A. Correia, R. Bennett, B. Pettersen, T.D. Ferlita, J.W. Costalas, K. Hunt, S. Donlon, C. Skrzynia, C. Farrell, F. Callif-Daley and C.W. Vockley, Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors, J Genet Couns 13 (2004), 83-114.
116. B.C. Turner, E. Harrold, E. Matloff, T. Smith, A.A. Gumbs, M. Beinfield, B. Ward, M. Skolnick, P.M. Glazer, A. Thomas and B.G. Haffty, BRCA1/ BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations, J Clin Oncol 17 (1999), 3017-3024.
117. US Food and Drug Administration, Center for Devices and Radiological Health, CLIA - Clinical Laboratory Improvement Amendments. Available at http://www.fda.gov/cdrh/clia/ (accessed November 30, 2006).
118. R.B. van der Luijt, P.H.A. van Zon, R.P.M. Jansen, C.J.M. van der Sijs-Bos, C.C. Warlam-Rodenhuis and M.G.E.M. Ausems, De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer, J Med Genet 38 (2001), 102-105.
119. M.S. van Roosmalen, P.F.M. Stalmeier, L.C.G. Verhoef, J.E.H.M. Hoekstra-Weebers, J.C. Oosterwijk, N. Hoogerbrugge, U. Moog and W.A.J. van Daal, Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation, Brit J Cancer 90 (2004), 333-342.
120. M.S. van Roosmalen, P.F.M. Stalmeier, L.C.G. Verhoef, J.E.H.M. Hoekstra-Weebers, J.C. Oosterwijk, N. Hoogerbrugge, U. Moog and W.A.J. van Daal, Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers, J Clin Oncol 22 (2004), 3293-3301.
121. T.C. van Sprundel, M.K. Schmidt, M.A. Rookus, R. Brohet, C.J. van Asperen, E.J.Th Rutgers, L.J. van't Veer and RAEM Tollenaar, Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 carriers, Brit J Cancer 93 (2005), 287-292.
122. C. H. Wade and B.S. Wilfond, Ethical and clinical practice considerations for genetic counselors related to direct-to-consumer marketing of genetic tests, Am J Med Genet Part C (Sem Med Genet) 142C (2006), 284-292.
123. J.E. Wagner, J. Tolar, O. Levran, T. Scholl, A. Deffenbaugh, J. Satagopan, L. Ben Porat, K. Mah, S.D. Batish, D.I. Kutler, M.L. MacMillan, H. Hanenberg and A.D. Auerbach, Germline mutations in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia, Blood 103 (2004), 3226-3229.
124. T. Walsh, S. Casadei, K.H. Coats, E. Swisher, S.M. Stray, J. Higgins, K.C. Roach, J. Mandell, M.K. Lee, S. Ciernikova, L. Foretova, P. Soucek and M.C. King, Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer, JAMA 295 (2006), 1379-1388.
125. C. Wang, R. Gonzalez, K.J. Milliron, V.J. Strecher and S.D. Merajver, Genetic counseling for BRCA1/2: A randomized controlled trial of two strategies to facilitate the education and counseling process, Am J Med Genet 134A (2005), 66-73.
126. V.O. Wang, Commentary: What is and is not telephone counseling? J Genet Couns 9 (2000), 73-82.
127. J.N. Weitzel, S.M. McCaffrey, R. Nedelcu, D.J. MacDonald, K.R. Blazer and C.A. Cullinane, Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis, Arch Surg 138 (2003), 1323-1328.
128. A.S. Whittemore, R.R. Balise, P.D.P. Pharoah, R.A. DiCioccio, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), I. Oakley-Girvan, S.J. Ramus, M. Daly, M.B. Usinowicz, K. Garlinghouse-Jones, B.A.J. Ponder, S. Buys, R. Senie, I. Andrulis, E. John, J.L. Hopper and M.S. Piver, Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations, Brit J Cancer 91 (2004), 1911-1915.
129. A.J. Wolfberg, Genes on the web - direct-to-consumer marketing, N Engl J Med 355 (2006), 543-545.